Autopsy report · NCT04405102

COVID-19 Ozanimod Intervention Study

“Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 8 months before it stopped.
• 43 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Ozanimod; Standard of care

Participants

43

Sites

3

Countries

Canada

Trials that died the same way

• The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study
  “Due to difficulty in recruiting patients, the Sponsor decided to prematurely stop the study” (63% match in meaning)
• Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients
  “the emergence of the omicron variant of COVID-19 lead to insufficient enrollment” (63% match in meaning)
• Assessment of Artificial Intelligence Algorithms for ROTEM
  “The study was stopped because it was considered unlikely that the required number of patients could be prospectively recruited across the participating study centers.” (62% match in meaning)
• Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
  “The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible” (59% match in meaning)
• Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
  “The rate of inclusion is too low to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives. The sponsor has decided to prematurely stop inclusions on January 13, 2022.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.